Spots Global Cancer Trial Database for Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Official Title: A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)
Study ID: NCT02665650
Conditions
Study Description
Brief Summary: The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Mayo Clinic, Scottsdale, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
University of Miami Sylvester Comprehensive Cancer Center, Coral Gables, Florida, United States
Mayo Clinic, Jacksonville, Florida, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Washington University Medical Center, Saint Louis, Missouri, United States
Providence Portland Medical Center, Providence Cancer Center, Portland, Oregon, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Institut Catala d'Oncologia (ICO) L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
Fundacion Privada Instituto de Investigacion Oncologica de Vall Hebron, Barcelona, , Spain
Hospital Universitario 12 de Octubre, Servicio de Hematologia, Madrid, , Spain
Salamanca University Hospital, Salamanca, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
